Chicago Cholangiocarcinoma Symposium

Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.

Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.

Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than the preoperative setting.

Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.

Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.

Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.

Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.